NICE Refuses Entyvio for Crohn’s NHS Patients in UK

NICE Refuses Entyvio for Crohn’s NHS Patients in UK
EntyvioThe National Institute for Health and Care Excellence (NICE), the provider of national guidance and advice to improve health and social care in the United Kingdom, published a draft guidance advising against the use of Entyvio by patients in the National Health System. The drug developed by Millennium Pharmaceuticals is intended for the treatment of Crohn's disease, a type of inflammatory bowel disease (IBD). The decision to recommend against the use of Entyvio by NHS patients is based on uncertain evidence, as well as on the unlikely nature that the drug would represent good value, as announced in a press release. In addition, NICE finds particularly concerning the uncertainty whether Entyvio is not as effective as other treatments that are currently available on the market. “Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared to other treatments," explained the director of NICE's health
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *